SOPHiA GENETICS SA (SOPH)
NasdaqGS · USD · Healthcare · Health Information Services
$7.52 (+2.31%) as of
Key statistics
- Market cap
- 640.16M
- Forward P/E
- -15.04
- EPS (TTM)
- -1.16
- Dividend yield
- 0.00%
- 52-week range
- 3.83 – 8.98
- Beta
- 0.95
- Revenue (TTM)
- 86.17M
- Profit margin
- -93.86%
- Analyst target
- $9.75
- Volume
- 261.14k
About SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.
- Sector
- Healthcare
- Industry
- Health Information Services
- Headquarters
- Rolle, Switzerland
- Employees
- 415
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.